Related Experiment Video

Updated: Jul 9, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Non-receptor tyrosine kinase inhibitors in lung cancer

Olwen Hahn1, Ravi Salgia

  • 1Department of Medicine, Section of Hematology, Oncology, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Il 60637, USA.

Anti-Cancer Agents in Medicinal Chemistry
|November 30, 2007
PubMed

Insights

Lung cancer remains a leading cause of death, with current therapies often ineffective. This review explores novel agents targeting non-receptor tyrosine kinases, crucial oncogenes in lung cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Lung cancer is a significant cause of cancer mortality worldwide.
  • Conventional cytotoxic chemotherapies demonstrate limited efficacy in treating lung cancer.
  • Emerging research focuses on targeted therapies for aberrant cellular pathways in lung cancer.

Purpose of the Study:

  • To review the role of non-receptor tyrosine kinases in lung cancer.
  • To discuss the development of therapeutic agents targeting these kinases.

Main Methods:

  • Literature review of scientific articles and clinical studies.
  • Analysis of the function of non-receptor tyrosine kinases in lung cancer pathogenesis.
  • Examination of current and emerging targeted therapies.

Main Results:

  • Non-receptor tyrosine kinases are implicated in key cellular processes vital for lung cancer growth and survival.
  • Targeting these kinases represents a promising strategy for novel lung cancer treatments.
  • Several agents targeting non-receptor tyrosine kinases are under investigation or in clinical development.

Conclusions:

  • Non-receptor tyrosine kinases are critical oncogenes in lung cancer.
  • Targeted therapies against these kinases offer a potential advancement over traditional chemotherapy.
  • Further research and development of these agents are warranted for improved lung cancer patient outcomes.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: